Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say

Teva Pharmaceutical Industries Ltd. (TEVA) reported $3.89 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 1.9%. EPS of $0.52 for the same period compares to $0.48 a year ago.The reported revenue represents a surprise of -1.92% over the Zacks Consensus Estimate of $3.97 billion. With the consensus EPS estimate being $0.47, the EPS surprise was +10.64%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- United States- Other: $109 million compared to the $110.05 million average estimate based on four analysts. The reported number represents a change of -18.1% year over year. Geographic Revenue- Europe- AJOVY: $58 million versus the four-analyst average estimate of $56.74 million. The reported number represents a year-over-year change of +13.7%. Geographic Revenue- International Markets- COPAXONE: $10 million versus $10.67 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -16.7% change. Geographic Revenue- International Markets- Generic products: $468 million versus the four-analyst average estimate of $487.47 million. The reported number represents a year-over-year change of -1.9%. Geographic Revenue- Europe- COPAXONE: $42 million compared to the $43.68 million average estimate based on four analysts. The reported number represents a change of -26.3% year over year. Geographic Revenue- Europe- Generic products: $989 million versus $991.61 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.5% change. Geographic Revenue- Europe- Other: $50 million versus the four-analyst average estimate of $95.70 million. The reported number represents a year-over-year change of -46.8%. Geographic Revenue- Europe- Respiratory products: $55 million compared to the $60.84 million average estimate based on four analysts. The reported number represents a change of -16.7% year over year. Geographic Revenue- International Markets- Other: $61 million versus $94.61 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -33% change. Geographic Revenue- United States: $1.91 billion compared to the $1.87 billion average estimate based on four analysts. The reported number represents a change of +10.7% year over year. Revenue- COPAXONE- Total: $106 million versus $84.97 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.1% change. Revenue- API sales to third parties: $130 million versus the two-analyst average estimate of $115.17 million. The reported number represents a year-over-year change of +1.6%. View all Key Company Metrics for Teva Pharmaceutical Industries here>>>Shares of Teva Pharmaceutical Industries have returned +18.6% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks